Tonix Pharmaceuticals posting a volatile trading session after posting data from its cyclobenzaprine study at Seattle symposium


Tonix Pharmaceuticals (TNXP -4.8%) reverses early gains to trade lower today, despite posting results from its nonclinical studies of cyclobenzaprine, the active ingredient of its lead candidate, TNX-102 sublingual tablet, at the International Pain Society's Ninth World Congress on Myofascial Pain Syndrome and Fibromyalgia Syndrome in Seattle, Washington.

The company notes that cyclobenzaprine exerts multiple effects on serotonergic and adrenergic neurotransmission, and that TNX-102 SL exerts pharmacological effects distinct from those exerted by products approved by the Food and Drug Administration for the management of fibromyalgia and PTSD.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs